Sugi Predict

Sugi Predict / Compounds / SCHEMBL6638898

SCHEMBL6638898

SCHEMBL6638898

CC(C)(C)OC(=O)NC(Cc1ccccc1)C(=O)Nc1ccc2c(-c3ccncc3)c(-c3ccc(F)cc3)[nH]c2n1

nearest known ligand 0.58

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 7/20 0.58
▸ MAPK13 O15264 6/20 0.58
▸ MAPK12 P53778 6/20 0.58
▸ MAPK11 Q15759 6/20 0.58
▸ SCN9A Q15858 5/20 0.46
▸ CTSS P25774 6/20 0.45
▸ CTSK P43235 5/20 0.45
▸ CTSB P07858 2/20 0.43
▸ CTSL P07711 1/20 0.43
▸ CCKAR P32238 1/20 0.40
▸ CCKBR P32239 1/20 0.40
▸ HDAC8 Q9BY41 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6642607 0.93 MAPK13 (0.55) MAPK14MAPK13MAPK12MAPK11SCN9A
SCHEMBL6642806 0.93 MAPK13 (0.56) MAPK14MAPK13MAPK12MAPK11SCN9A
SCHEMBL6639248 0.93 MAPK14 (0.56) MAPK14MAPK13MAPK12MAPK11SCN9A
SCHEMBL6638914 0.92 MAPK13 (0.55) MAPK14MAPK13MAPK12MAPK11SCN9A
SCHEMBL6640798 0.89 MAPK14 (0.61) MAPK14MAPK13MAPK12MAPK11SCN9A
SCHEMBL6642435 0.89 MAPK13 (0.55) MAPK14MAPK13MAPK12MAPK11SCN9A
SCHEMBL6641827 0.88 MAPK14 (0.52) MAPK14MAPK13MAPK12MAPK11SCN9A
SCHEMBL6638395 0.87 MAPK14 (0.58) MAPK14MAPK13MAPK12MAPK11SCN9A
SCHEMBL6641557 0.86 MAPK13 (0.56) MAPK14MAPK13MAPK12MAPK11SCN9A
SCHEMBL6639546 0.86 MAPK14 (0.65) MAPK14MAPK13MAPK12MAPK11SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0948495-B1 ARYL AND HETEROARYL SUBSTITUTED FUSED PYRROLE ANTIINFLAMMATORY AGENTS AMGEN INC (US) 2004-04-14 — — EP claimed
US-20030096819-A1 Aryl and heteroaryl substituted fused pyrrole anti-inflammatory agents AMGEN INC. 2003-05-22 — — US claimed
US-6180643-B1 ANTAGONIST OF INTERLEUKINS, TUMOR NECROSIS FACTOR AMGEN INC. 2001-01-30 — — US claimed
EP-0948495-B1 ARYL AND HETEROARYL SUBSTITUTED FUSED PYRROLE ANTIINFLAMMATORY AGENTS AMGEN INC (US) 2004-04-14 — — EP disclosed
US-6605634-B2 Tumor necrosis factor alpha and interleukin-1 (IL-1) mediated diseases; pain, diabetes; cyclooxygenase inhibition AMGEN, INC. 2003-08-12 — — US disclosed
US-20030096819-A1 Aryl and heteroaryl substituted fused pyrrole anti-inflammatory agents AMGEN INC. 2003-05-22 — — US disclosed
US-6440973-B1 Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents AMGEN INC. 2002-08-27 — — US disclosed
US-6180643-B1 ANTAGONIST OF INTERLEUKINS, TUMOR NECROSIS FACTOR AMGEN INC. 2001-01-30 — — US disclosed
WO-1998022457-A9 ARYL AND HETEROARYL SUBSTITUTED FUSED PYRROLE ANTIINFLAMMATORY AGENTS — 1998-08-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096819-A1 Aryl and heteroaryl substituted fused pyrrole anti-inflammatory agents TNF, IL1A, IL6 MAPK14 2705/4885MAPK13 2534/4885MAPK12 1983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.